文献速递免疫规划慢病防控与筛查

通过基于人群的监测识别宫颈癌前病变的趋势——人乳头状瘤病毒疫苗影响监测项目,美国五个监测点,2008—2022年

Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008-2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2025-02-27

美国CDC通过五站点人乳头状瘤病毒疫苗影响监测项目,分析2008—2022年宫颈癌筛查发现的宫颈上皮内瘤变2级及以上(CIN2+)和3级及以上(CIN3+)病变的发病率趋势。在20—24岁接受筛查的女性中,CIN2+发病率下降79%,CIN3+下降80%;25—29岁筛查女性CIN3+下降37%。数据与HPV疫苗在最可能接种年龄组女性中预防宫颈癌前病变的显著影响一致,支持现有推荐在常规推荐年龄为儿童接种疫苗作为癌症预防措施。

要点

  • 20—24岁筛查女性CIN2+发病率2008—2022年下降79%,CIN3+下降80%。
  • 25—29岁筛查女性CIN3+发病率同期下降37%。
  • 数据支持现有推荐在常规推荐年龄为儿童接种HPV疫苗作为癌症预防措施。

核心结论

  • 数据与HPV疫苗在最可能接种年龄组女性中预防宫颈癌前病变的显著影响一致,并支持现有推荐在常规推荐年龄为儿童接种疫苗作为癌症预防措施。

研究设计与样本

  • 美国CDC通过五站点人乳头状瘤病毒疫苗影响监测项目,分析2008—2022年宫颈癌筛查发现的CIN2+和CIN3+病变的发病率趋势。

主要发现

  • 20—24岁接受宫颈癌筛查的女性中,CIN2+发病率2008—2022年下降79%,CIN3+下降80%。
  • 25—29岁接受筛查的女性中,CIN3+发病率2008—2022年下降37%。

临床怎么用

  • 现有推荐为在常规推荐年龄为儿童接种HPV疫苗作为癌症预防措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2006, human papillomavirus (HPV) vaccine was first recommended in the United States to prevent cancers and other diseases caused by HPV; vaccination coverage increased steadily through 2021, and increasing numbers of young women had received HPV vaccine as children or adolescents. Since 2008, CDC has monitored incidence of precancerous lesions (cervical intraepithelial neoplasia [CIN] grades 2-3 and adenocarcinoma in situ [AIS], collectively CIN2+), which are detected through cervical cancer screening and can be used as an intermediate outcome for monitoring vaccination impact, via the five-site Human Papillomavirus Vaccine Impact Monitoring Project. This analysis describes trends in incidence of CIN2+ and CIN3+ (i.e., CIN grade 3 and AIS) lesions during 2008-2022. Among women aged 20-24 years who were screened for cervical cancer, rates during 2008-2022 decreased for CIN2+ by 79%, and for CIN3+ by 80%. In the same period, CIN3+ rates among screened women aged 25-29 years decreased by 37%. These data are consistent with considerable impact of HPV vaccination for preventing cervical precancers among women in the age groups most likely to have been vaccinated, and support existing recommendations to vaccinate children at the routinely recommended ages as a cancer prevention measure.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Gargano JW, Stefanos R, Dahl RM, et al. Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008-2022. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014651. doi:10.15585/mmwr.mm7406a4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。